TY - JOUR
T1 - Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides
T2 - The results of a pilot study
AU - Caproni, Stefano
AU - Corbelli, Ilenia
AU - Pini, Luigi Alberto
AU - Cupini, Maria Letizia
AU - Calabresi, Paolo
AU - Sarchielli, Paola
PY - 2011/5
Y1 - 2011/5
N2 - Aims: This study was aimed to verify changes in the levels of hypothalamic neuropeptides in migraineurs under preventive treatment with amitryptiline and flunarizine. Thirty-nine migraine patients with a body mass index 2 and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months. Orexin-A, orexin-B and neuropeptide-Y plasma levels were measured at the basal time, at the 1st, 2nd and 3rd months of preventive treatment. Results: A statistically significant reduction in plasma orexin-A and orexin-B levels emerged in both groups. Conversely, plasma neuropeptide-Y levels were markedly increased, with the highest levels at the 2nd and 3rd months, in both patient groups. Orexin-A levels were also negatively correlated to weight gain in both groups during the treatment period. Conclusions: These results suggest that changes in the levels of hypothalamic orexinergic peptides may contribute to body weight increase occurring in migraineurs during amitryptiline or flunarizine prophylactic treatment.
AB - Aims: This study was aimed to verify changes in the levels of hypothalamic neuropeptides in migraineurs under preventive treatment with amitryptiline and flunarizine. Thirty-nine migraine patients with a body mass index 2 and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months. Orexin-A, orexin-B and neuropeptide-Y plasma levels were measured at the basal time, at the 1st, 2nd and 3rd months of preventive treatment. Results: A statistically significant reduction in plasma orexin-A and orexin-B levels emerged in both groups. Conversely, plasma neuropeptide-Y levels were markedly increased, with the highest levels at the 2nd and 3rd months, in both patient groups. Orexin-A levels were also negatively correlated to weight gain in both groups during the treatment period. Conclusions: These results suggest that changes in the levels of hypothalamic orexinergic peptides may contribute to body weight increase occurring in migraineurs during amitryptiline or flunarizine prophylactic treatment.
KW - amytryptiline
KW - Flunarizine
KW - migraine
KW - neuropeptide-Y
KW - orexin
UR - http://www.scopus.com/inward/record.url?scp=79953184308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953184308&partnerID=8YFLogxK
U2 - 10.1177/0333102410392605
DO - 10.1177/0333102410392605
M3 - Article
C2 - 21216871
AN - SCOPUS:79953184308
VL - 31
SP - 543
EP - 549
JO - Cephalalgia
JF - Cephalalgia
SN - 0333-1024
IS - 5
ER -